sq-11725 has been researched along with flecainide in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (36.84) | 29.6817 |
| 2010's | 9 (47.37) | 24.3611 |
| 2020's | 3 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Leung, TK; Nattel, S; Rivard, L; Schram, G; Shiroshita-Takeshita, A; Sinno, H | 1 |
| Amoussou, M; Kambiré, Y; Konaté, L; Millogo, GR; Nebié, LV; Niakara, A; Sib, E | 1 |
| Bradley, DJ; Caruthers, R; LaPage, MJ; von Alvensleben, JC | 1 |
| Klug, D; Vaksmann, G | 1 |
| Aziz, Z; Beaser, AD; Kohli, U; Nayak, HM | 2 |
| Belli, G; Brambilla, A; Capponi, G; De Simone, L; Favilli, S; Giovannini, M; Porcedda, G; Remaschi, G; Vannuccini, F | 1 |
| Abrams, DJ; Przybylski, R | 1 |
1 review(s) available for sq-11725 and flecainide
| Article | Year |
|---|---|
Current management of inherited arrhythmia syndromes associated with the cardiac ryanodine receptor.
Topics: Adrenergic beta-Antagonists; Flecainide; Humans; Mutation; Nadolol; Ryanodine Receptor Calcium Release Channel; Tachycardia, Ventricular | 2023 |
18 other study(ies) available for sq-11725 and flecainide
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
The pharmacological response of ischemia-related atrial fibrillation in dogs: evidence for substrate-specific efficacy.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channel Blockers; Coronary Disease; Diltiazem; Dogs; Electric Stimulation; Flecainide; Models, Animal; Nadolol; Phenethylamines; Potassium Channel Blockers; Refractory Period, Electrophysiological; Sodium Channel Blockers; Sulfonamides; Vagus Nerve | 2007 |
Right ventricular outflow tract tachycardia worsened during pregnancy.
Topics: Adult; Anti-Arrhythmia Agents; Catheter Ablation; Drug Therapy, Combination; Female; Flecainide; Hospitalization; Humans; Nadolol; Pregnancy; Pregnancy Complications, Cardiovascular; Tachycardia, Ventricular | 2015 |
Nadolol for Treatment of Supraventricular Tachycardia in Infants and Young Children.
Topics: Age of Onset; Anti-Arrhythmia Agents; Databases, Factual; Female; Flecainide; Humans; Infant; Infant, Newborn; Male; Michigan; Nadolol; Pediatrics; Retrospective Studies; Tachycardia, Supraventricular; Treatment Outcome | 2017 |
Efficacy of ivabradine to control ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia.
Topics: Adolescent; Anti-Arrhythmia Agents; Cardiovascular Agents; Electrocardiography; Exercise Test; Female; Flecainide; Humans; Ivabradine; Male; Nadolol; Tachycardia, Ventricular; Young Adult | 2018 |
A large deletion in RYR2 exon 3 is associated with nadolol and flecainide refractory catecholaminergic polymorphic ventricular tachycardia.
Topics: Adolescent; Anti-Arrhythmia Agents; Exons; Flecainide; Gene Deletion; Humans; Male; Nadolol; Ryanodine Receptor Calcium Release Channel; Tachycardia, Ventricular | 2019 |
Ventricular arrhythmia suppression with ivabradine in a patient with catecholaminergic polymorphic ventricular tachycardia refractory to nadolol, flecainide, and sympathectomy.
Topics: Adolescent; Cardiovascular Agents; Electrocardiography; Exercise Test; Flecainide; Humans; Ivabradine; Male; Nadolol; Phenotype; Sympathectomy; Tachycardia, Ventricular | 2020 |
Supraventricular tachycardias in the first year of life: what is the best pharmacological treatment? 24 years of experience in a single centre.
Topics: Action Potentials; Adrenergic beta-Antagonists; Age Factors; Anti-Arrhythmia Agents; Digoxin; Drug Therapy, Combination; Female; Flecainide; Heart Rate; Humans; Infant; Infant, Newborn; Male; Nadolol; Recurrence; Retrospective Studies; Sotalol; Tachycardia, Supraventricular; Time Factors; Treatment Outcome; Voltage-Gated Sodium Channel Blockers | 2021 |